Trial Profile
Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs MEDI 6469 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms OX40 SBRT
- 05 Mar 2019 Status changed from active, no longer recruiting to completed.
- 05 Mar 2019 Status changed from active, no longer recruiting to completed.
- 15 Aug 2018 Planned End Date changed from 1 Feb 2023 to 15 Jan 2019.